P039 Regional distribution of TCR Vδ1 and TCR Vδ2 cells in healthy and inflamed mucosa of inflammatory bowel disease
E. Tristan, A. Carrasco, A. Martín-Cardona, Y. Zabana, M. Aceituno, D. Horta, X. Andújar, I. Salvador, C. Loras, F. Fernández-Bañares, M. Esteve
Gastroenterology Department, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Terrassa. Centro de Investigación Biomédica en red de enfermedades hepáticas y digestivas CIBERehd, Gastroenterology Department, Terrassa, Spain
Background
Vδ1+ and Vδ2+ are TCRγδ lymphocytes of the gut intraepithelial compartment that recognise proteins without help of antigen-presenting cells. Its relevance in inflammatory bowel disease (IBD) is unknown.
Methods
To measure Vδ1+ and Vδ2+ in T-cell subtypes [CD4+, CD8+, double positive (DP,CD4+CD8+), double negative (DN,CD4−CD8−) and CD103+] of healthy and IBD inflammed gut mucosa.
Results
Twenty-six active IBD patients without immunosuppressants (
Conclusion
Healthy mucosa: reduction in ileum of total CD3+Vδ1+ due to CD3+CD8+Vδ1+ and CD3+DN_Vδ1+
CD3+Vδ1+ | 2,6 (1.2–5.7) | 11.0 (7.9–16.1) | 7.1 (5.1–9.6) | 0.001 |
CD3+CD8+Vδ1+ | 2.7 (1.3–5.6) | 13.4 (7.4–18.1) | 10.6 (6.3–15.6) | 0.005 |
CD3+DN_Vδ1+ | 29.8 (17.8–39.4) | 55.5 (37.7–72.4) | 51.2 (45.5–67.7) | 0.003 |
Ileal CD vs. ileal control: CD3+DN_Vδ2+ reduction and increase of Vδ1 and Vδ2 CD4+.
CD3+DN_Vδ2+ | 5.5 (1.9–9.7) | 15.9 (9.9–36) | 0.021 |
CD3+Vδ2+DN | 44.9 (27.1–56.9) | 69.60 (52.9–73.5) | 0.027 |
CD3+Vδ1+CD4+ | 6.1 (2.7–16.8) | 1.8 (0.5–4.0) | 0.043 |
CD3+Vδ2+CD4+ | 20.8 (6.6–45.3) | 2.5 (0–5.6) | 0.003 |
Colonic CD, UC vs. control: CD3+Vδ1+ decrease in CD and UC, and decrease of their subsets CD3+CD8+Vδ1+ and CD3+DN_Vδ1+. CD103+ and CD103− showed specular behaviour with CD3+DN_Vδ1+CD103+ and CD3+CD8+Vδ1+CD103+ decrease and CD3+DN_Vδ1+CD103− and CD3+CD8+Vδ1+CD103− increase both in UC and CD. A similar effect was observed for CD103+ and CD103− of CD3+DN_Vδ2+. CD3+Vδ1+CD4+ was increased in UC and ileal CD.
CD3+Vδ1+ | 2.1 (1.6–3.0) | 2.8 (1.9–20.6) | 7.1 (5.0–9.6) | 0.002 |
CD3+CD8+Vδ1+ | 2.3 (1.1–5.8) | 3.7 (2.8–23.7) | 10.6 (6.4–15.6) | 0.013 |
CD3+DN_Vδ1 | 18.9 (16.2–27.5) | 28.4 (20.5–61.2) | 51.2 (45.5–67.8) | 0.001 |
CD3+CD8+_Vδ1+CD103+ | 49.9 (17.2–60.9) | 45.0 (13.3–84.5) | 93.8 (87.7–98.4) | 0.002 |
CD3+CD8+Vδ1+CD103− | 50.0 (32.1–82.8) | 55.0 (15.5–86.7) | 6.1 (1.6–12.3) | 0.003 |
CD3+DN_Vδ1+CD103+ | 7.4 (2.9–14.9) | 48.5 (16.4–82.3) | 91.3 (76.3–96.1) | 0.001 |
CD3+DN_Vδ1+CD103− | 92.5 (85.1–97.1) | 51.5 (17.7–83.6) | 8.7 (3.8–23.6) | 0.001 |
CD3+DN_Vδ2+CD103+ | 6.5 (0.9–8.8) | 4.2 (0–30.0) | 59.8 (18.5–67.2) | 0.011 |
CD3+DN_Vδ2+CD103− | 93.5 (91.2–99.03) | 72.2 (33.8–97.9) | 37.5 (27.5–52.2) | 0.004 |
CD3+Vδ1+CD4+ | 4.6 (2.2–15.3) | 1.4 (0.7–5.8) | 0.6 (0.3–1.5) | 0.006 |
Reduction of Vδ1+ and Vδ2+, mainly of CD103+, may play a role in IBD pathophysiology by perpetuating inflammation. Increase of CD3+Vδ1+CD4+ in both Ileal CD and UC may compensate this decrease with a selective increase in ‘helper’ function.